



Bal Pharma Limited

To,
The Manager-listing
National Stock Exchange of India Ltd
Mumbai.

12.08.2013


Dear Sir,

Sub ; Out Come of the Board Meeting.

As already informed to the exchanges, the Board of Directors of the Company has met today and *inter alia* has approved the Un-Audited financial results of the Company for the quarter ended 30.06.2013. A copy of the financial results along with the limited review report issued by the Statutory Auditors of the Company is enclosed with this intimation.

Please take this intimation on record and treat this as compliance with the listing agreement.

Thanking You
For Bal Pharma Limited


Shailesh Siroya
Managing Director



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91-80 - 22354057 / 58

Email : balpharma@vsnl.com Website : www.balpharma.com

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bangalore - 560 099. Ph : 41570813 /19 Fax : 41570820



BAI PHARMA LIMITED
Regd Office: 21-22 Bommasandra Industrial Area Anekal Taluq, Bangalore 560 099
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2013

(in Lakhs)

Sr No:	Particulars	Quarter Ended			Year ended
		Unaudited			Audited
		30.06.2013	31.03.2013	30.06.2012	31.03.2013
1	Net Sales/Income from operations (Net of Excise Duty)	3,676.16	4,155.63	2,952.30	14,430.36
	Other Operating Income	94.05	126.24	46.60	361.08
	Net Income from Sales/Services	3,770.21	4,281.87	2,998.90	14,791.44
2	Expenditure				
	a) Increase/decrease in stock in trade and WIP	(58.88)	100.48	(254.20)	244.71
	b) Consumption of Raw Materials/ Packing Material	1,778.68	2,118.81	1,656.48	7,209.61
	c) Purchase of Stock in Trade	74.57	121.64	55.92	440.16
	d)Employee Cost	655.30	588.24	585.59	2,357.48
	e) Depreciation and amortisation expenses	152.26	183.66	95.65	481.22
	f) Other Expenditure	877.96	775.82	655.95	2,817.61
	g) Total	3,479.89	3,888.64	2,795.39	13,550.78
3	Profit from Operations before other Income, interest and Exceptional items(1-2)	290.32	393.23	203.51	1,240.66
4	Other Non-operating Income	7.90	36.19	10.36	65.93
5	Profit before Interest and Exceptional items (3+4)	298.22	429.42	213.87	1,306.59
6	Finance Costs	181.99	200.55	188.34	797.68
7	Profit after Interest but before Exceptional items	116.23	228.87	25.53	508.91
8	Exceptional items	-	-	-	-
9	Profit/Loss from ordinary activities Before Tax (7-8)	116.23	228.87	25.53	508.91
10	Tax expenses	24.78	16.68	6.32	80.56
11	Net Profit /Loss from ordinary Activities after Tax	91.45	212.19	19.21	428.35
12	Extra ordinary items	-	-	-	-
13	Net Profit / Loss for the period	91.45	212.19	19.21	428.35
14	Paid-up Equity Share capital(face value of Rs 10 each)	1,057.36	1,057.36	1,057.36	1,057.36
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				2,948.22
16	EPS (in Rs.)				
	a) Basic & Diluted	0.86	2.01	0.18	4.05
17	Public shareholding				
	- Number of Shares	5,142,086	5,142,086	5,142,086	5,142,086
	- Percentage of shareholding	48.63	48.63	48.63	48.63
18	Promoters & Promoter group Shareholding				
	a) Pledged / Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of shareholding	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	5,431,538	5,431,538	5,431,538	5,431,538
	- Percentage of shareholding	51.37	51.37	51.37	51.37

Notes:

- The above Un-Audited financial results, as reviewed by the Audit Committee were approved by the Board of Directors at their meeting held on 12.08.2013
- The Statutory Auditors of the Company have conducted a limited review on the Un-Audited financial results of the company for the quarter ended 30.06.2013.
- Investor grievances: Outstanding at the beginning of the quarter : Nil . received during the quarter: 02 resolved during the quarter:02 pending at the end of the quarter: Nil
- As Company deals with a single product i.e pharmaceuticals, segment wise figures are not furnished

Bangalore
12th August 2013

By order of the Board of Directors
For BAI Pharma limited
Shailesh Siroya
Managing Director

